Bulk Manufacturer of Controlled Substances Application: Johnson Matthey, Inc., 5477-5478 [2019-02882]
Download as PDF
<![CDATA[
5477
Federal Register / Vol. 84, No. 35 / Thursday, February 21, 2019 / Notices
innovative healthcare products. These
comments are consistent with the
United States’ previous recognition that
this merger has the potential to generate
benefits by improving the quality and
lowering the costs of healthcare
services.80
VI. Conclusion
After careful consideration of the
public comments, the United States
continues to believe that the proposed
Final Judgment, as drafted, provides an
effective and appropriate remedy for the
antitrust violations alleged in the
Complaint, and is therefore in the
public interest. The United States will
move this Court to enter the proposed
Final Judgment after the comments and
this response are published as required
by 15 U.S.C. § 16(d).
amozie on DSK3GDR082PROD with NOTICES1
Dated: February 13, 2019
Respectfully submitted,
Jay D. Owen,
Shobitha Bhat,
Natalie R. Melada,
U.S. Department of Justice,
Antitrust Division,
450 Fifth Street NW, Suite 4100,
Washington, D.C. 20530,
Tel.: (202) 598-2987,
Fax: (202) 616-2441,
E-mail: Jay.Owen@usdoj.gov.
Registrants listed below has
applied for and been granted
registration by the Drug Enforcement
Administration (DEA) as importers of
schedule I or schedule II controlled
substances.
SUMMARY:
The
companies listed below applied to be
registered as importers of various basic
classes of controlled substances.
Information on the previously published
notices is listed in the table below. No
comments or objections were submitted
and no requests for hearing were
submitted for these notices.
SUPPLEMENTARY INFORMATION:
[FR Doc. 2019–02846 Filed 2–20–19; 8:45 am]
BILLING CODE 4410–11–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–392]
Importer of Controlled Substances
Registration
ACTION:
Notice of registration.
Company
FR docket
Mylan Technologies, Inc. .............................................................................................................................
Noramco Inc. ................................................................................................................................................
Arizona Department of Corrections ..............................................................................................................
83 FR 64160
83 FR 64159
83 FR 64364
The DEA has considered the factors in
21 U.S.C. 823, 952(a) and 958(a) and
determined that the registration of the
listed registrants to import the
applicable basic classes of schedule I or
II controlled substances is consistent
with the public interest and with United
States obligations under international
treaties, conventions, or protocols in
effect on May 1, 1971. The DEA
investigated each company’s
maintenance of effective controls
against diversion by inspecting and
testing each company’s physical
security systems, verifying each
company’s compliance with state and
local laws, and reviewing each
company’s background and history.
Therefore, pursuant to 21 U.S.C.
952(a) and 958(a), and in accordance
with 21 CFR 1301.34, the DEA has
granted a registration as an importer for
schedule I or schedule II controlled
substances to the above listed
companies.
DEPARTMENT OF JUSTICE
Dated: January 29, 2019.
John J. Martin,
Assistant Administrator.
SUPPLEMENTARY INFORMATION:
[FR Doc. 2019–02871 Filed 2–20–19; 8:45 am]
BILLING CODE 4410–09–P
80 See ‘‘Justice Department Requires CVS and
Aetna to Divest Aetna’s Medicare Individual Part D
VerDate Sep<11>2014
17:08 Feb 20, 2019
Jkt 247001
Drug Enforcement Administration
[Docket No. DEA–392]
Bulk Manufacturer of Controlled
Substances Application: Johnson
Matthey, Inc.
ACTION:
Notice of application.
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before March 25, 2019. Such persons
may also file a written request for a
hearing on the application on or before
March 25, 2019.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152.
DATES:
Published
December 13, 2018.
December 13, 2018.
December 14, 2018.
implementation of 21 CFR part 1301,
incident to the registration of
manufacturers, distributors, dispensers,
importers, and exporters of controlled
substances (other than final orders in
connection with suspension, denial, or
revocation of registration) has been
redelegated to the Assistant
Administrator of the DEA Diversion
Control Division (‘‘Assistant
Administrator’’) pursuant to section 7 of
28 CFR part 0, appendix to subpart R.
In accordance with 21 CFR
1301.33(a), this is notice that on October
12, 2018, Johnson Matthey Inc., 2003
Nolte Drive, West Deptford, New Jersey
08066, applied to be registered as a bulk
manufacturer of the following basic
classes of controlled substances listed in
schedule I & II.
Controlled substance
Drug
code
Schedule
The
Attorney General has delegated his
authority under the Controlled
Substances Act to the Administrator of
the Drug Enforcement Administration
(DEA), 28 CFR 0.100(b). Authority to
exercise all necessary functions with
respect to the promulgation and
Gamma Hydroxybutyric Acid.
Marihuana .................
Tetrahydrocannabinols.
Dihydromorphine ......
Difenoxin ...................
Amphetamine ...........
Methamphetamine ....
Lisdexamfetamine ....
Methylphenidate .......
Nabilone ...................
Prescription Drug Plan Business to Proceed with
Merger,’’ available at https://www.justice.gov/opa/
pr/justice-department-requires-cvs-and-aetnadivest-aetna-s-medicare-individual-part-d.
PO 00000
Frm 00074
Fmt 4703
Sfmt 4703
E:\FR\FM\21FEN1.SGM
21FEN1
2010
I
7360
7370
I
I
9145
9168
1100
1105
1205
1724
7379
I
I
II
II
II
II
II
5478
Federal Register / Vol. 84, No. 35 / Thursday, February 21, 2019 / Notices
Controlled substance
Drug
code
Cocaine ....................
Codeine ....................
Dihydrocodeine .........
Oxycodone ...............
Hydromorphone ........
Diphenoxylate ...........
Ecgonine ...................
Hydrocodone ............
Meperidine ................
Methadone ................
Methadone intermediate.
Morphine ...................
Thebaine ...................
Opium tincture ..........
Oxymorphone ...........
Noroxymorphone ......
Alfentanil ...................
Remifentanil ..............
Sufentanil ..................
Tapentadol ................
Fentanyl ....................
Schedule
9041
9050
9120
9143
9150
9170
9180
9193
9230
9250
9254
II
II
II
II
II
II
II
II
II
II
II
9300
9333
9630
9652
9668
9737
9739
9740
9780
9801
II
II
II
II
II
II
II
II
II
II
below. No comments or objections were
submitted for this notice.
Company
Sigma Aldrich
Research.
FR docket
Published
83 FR 54613
October 30, 2018.
The DEA has considered the factors in
21 U.S.C. 823(a) and determined that
the registration of this registrant to
manufacture the applicable basic classes
of controlled substances is consistent
with the public interest and with United
States obligations under international
treaties, conventions, or protocols in
effect on May 1, 1971. The DEA
investigated the company’s maintenance
of effective controls against diversion by
inspecting and testing the company’s
physical security systems, verifying the
company’s compliance with state and
local laws, and reviewing the company’s
background and history.
Therefore, pursuant to 21 U.S.C.
823(a), and in accordance with 21 CFR
1301.33, the DEA has granted a
registration as a bulk manufacturer to
the above listed company.
In reference to drug codes 7360
(Marijuana), and 7370 (THC), the
company plans to bulk manufacture
these drugs as synthetic. No other
activities for these drug codes are
authorized for this registration.
Dated: January 29, 2019.
John J. Martin,
Assistant Administrator.
Dated: February 11, 2019.
John J. Martin,
Assistant Administrator.
Myoderm ......
83 FR 66751
December 27, 2018.
The DEA has considered the factors in
21 U.S.C. 823, 952(a) and 958(a) and
determined that the registration of the
listed registrant to import the applicable
basic class of schedule II controlled
substances is consistent with the public
interest and with United States
obligations under international treaties,
conventions, or protocols in effect on
May 1, 1971. The DEA investigated the
company’s maintenance of effective
controls against diversion by inspecting
and testing the company’s physical
security systems, verifying the
company’s compliance with state and
local laws, and reviewing the company’s
background and history.
Therefore, pursuant to 21 U.S.C.
952(a) and 958(a), and in accordance
with 21 CFR 1301.34, the DEA has
granted a registration as an importer for
schedule II controlled substances to the
above listed company.
Dated: February 11, 2019.
John J. Martin,
Assistant Administrator.
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Drug Enforcement Administration
[Docket No. DEA–392]
[Docket No. DEA–392]
Importer of Controlled Substances
Registration
Bulk Manufacturer of Controlled
Substances Registration
ACTION:
Notice of registration.
The registrant listed below
has applied for and has been granted a
registration by the Drug Enforcement
Administration (DEA) as a bulk
manufacturer of various classes of
schedule I and II controlled substances.
SUPPLEMENTARY INFORMATION: The
company listed below applied to be
registered as a bulk manufacturer of
various basic classes of controlled
substances. Information on the previous
published notice are listed in the table
Company
Jkt 247001
Importer of Controlled Substances
Registration
ACTION:
Notice of registration.
The registrants listed below
have applied for and been granted
registration by the Drug Enforcement
Administration (DEA) as importers of
schedule I or schedule II controlled
substances.
The
companies listed below applied to be
registered as importers of various basic
classes of controlled substances.
Information on previously published
notices is listed in the table below. No
comments or objections were submitted
and no requests for hearing were
submitted for these notices.
SUPPLEMENTARY INFORMATION:
FR docket
Janssen Pharmaceuticals, Inc ..........................................
Lipomed ............................................................................
Akorn, Inc ..........................................................................
Cambridge Isotope Laboratories ......................................
GE Healthcare ..................................................................
Fisher Clinical Services, Inc .............................................
17:08 Feb 20, 2019
[Docket No. DEA–392]
SUMMARY:
The registrant listed below
has applied for and has been granted
registration by the Drug Enforcement
Administration (DEA) as an importer of
schedule II controlled substances.
SUPPLEMENTARY INFORMATION: The
company listed below applied to be
registered as an importer of a basic class
of controlled substance. Information on
the previously published notice is listed
in the table below. No comments or
objections were submitted and no
requests for hearing were submitted for
this notice.
SUMMARY:
Notice of registration.
SUMMARY:
amozie on DSK3GDR082PROD with NOTICES1
Published
BILLING CODE 4410–09–P
BILLING CODE 4410–09–P
VerDate Sep<11>2014
FR docket
[FR Doc. 2019–02870 Filed 2–20–19; 8:45 am]
[FR Doc. 2019–02869 Filed 2–20–19; 8:45 am]
[FR Doc. 2019–02882 Filed 2–20–19; 8:45 am]
ACTION:
Company
PO 00000
83
83
83
83
83
83
FR
FR
FR
FR
FR
FR
Frm 00075
58598
58601
60896
60897
60899
60900
Fmt 4703
Published
...................................................................
...................................................................
...................................................................
...................................................................
...................................................................
...................................................................
Sfmt 4703
E:\FR\FM\21FEN1.SGM
21FEN1
November
November
November
November
November
November
20,
20,
27,
27,
27,
27,
2018.
2018.
2018.
2018.
2018.
2018.
]]>Agencies
[Federal Register Volume 84, Number 35 (Thursday, February 21, 2019)]
[Notices]
[Pages 5477-5478]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-02882]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-392]
Bulk Manufacturer of Controlled Substances Application: Johnson
Matthey, Inc.
ACTION: Notice of application.
-----------------------------------------------------------------------
DATES: Registered bulk manufacturers of the affected basic classes, and
applicants therefore, may file written comments on or objections to the
issuance of the proposed registration on or before March 25, 2019. Such
persons may also file a written request for a hearing on the
application on or before March 25, 2019.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/DPW,
8701 Morrissette Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: The Attorney General has delegated his
authority under the Controlled Substances Act to the Administrator of
the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority
to exercise all necessary functions with respect to the promulgation
and implementation of 21 CFR part 1301, incident to the registration of
manufacturers, distributors, dispensers, importers, and exporters of
controlled substances (other than final orders in connection with
suspension, denial, or revocation of registration) has been redelegated
to the Assistant Administrator of the DEA Diversion Control Division
(``Assistant Administrator'') pursuant to section 7 of 28 CFR part 0,
appendix to subpart R.
In accordance with 21 CFR 1301.33(a), this is notice that on
October 12, 2018, Johnson Matthey Inc., 2003 Nolte Drive, West
Deptford, New Jersey 08066, applied to be registered as a bulk
manufacturer of the following basic classes of controlled substances
listed in schedule I & II.
------------------------------------------------------------------------
Controlled substance Drug code Schedule
------------------------------------------------------------------------
Gamma Hydroxybutyric Acid............. 2010 I
Marihuana............................. 7360 I
Tetrahydrocannabinols................. 7370 I
Dihydromorphine....................... 9145 I
Difenoxin............................. 9168 I
Amphetamine........................... 1100 II
Methamphetamine....................... 1105 II
Lisdexamfetamine...................... 1205 II
Methylphenidate....................... 1724 II
Nabilone.............................. 7379 II
[[Page 5478]]
Cocaine............................... 9041 II
Codeine............................... 9050 II
Dihydrocodeine........................ 9120 II
Oxycodone............................. 9143 II
Hydromorphone......................... 9150 II
Diphenoxylate......................... 9170 II
Ecgonine.............................. 9180 II
Hydrocodone........................... 9193 II
Meperidine............................ 9230 II
Methadone............................. 9250 II
Methadone intermediate................ 9254 II
Morphine.............................. 9300 II
Thebaine.............................. 9333 II
Opium tincture........................ 9630 II
Oxymorphone........................... 9652 II
Noroxymorphone........................ 9668 II
Alfentanil............................ 9737 II
Remifentanil.......................... 9739 II
Sufentanil............................ 9740 II
Tapentadol............................ 9780 II
Fentanyl.............................. 9801 II
------------------------------------------------------------------------
In reference to drug codes 7360 (Marijuana), and 7370 (THC), the
company plans to bulk manufacture these drugs as synthetic. No other
activities for these drug codes are authorized for this registration.
Dated: February 11, 2019.
John J. Martin,
Assistant Administrator.
[FR Doc. 2019-02882 Filed 2-20-19; 8:45 am]
BILLING CODE 4410-09-P
